Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. Fujimoto N, et al. Among authors: peyton m. Cancer Res. 2005 Dec 15;65(24):11478-85. doi: 10.1158/0008-5472.CAN-05-1977. Cancer Res. 2005. PMID: 16357156
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Cai D, et al. Among authors: peyton m. Cancer Res. 2010 Aug 15;70(16):6477-85. doi: 10.1158/0008-5472.CAN-10-0005. Epub 2010 Jul 27. Cancer Res. 2010. PMID: 20663904 Free PMC article.
Gefitinib versus cetuximab in lung cancer: round one.
Minna JD, Peyton MJ, Gazdar AF. Minna JD, et al. J Natl Cancer Inst. 2005 Aug 17;97(16):1168-9. doi: 10.1093/jnci/dji247. J Natl Cancer Inst. 2005. PMID: 16106015 No abstract available.
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA. Zhou BB, et al. Among authors: peyton m. Cancer Cell. 2006 Jul;10(1):39-50. doi: 10.1016/j.ccr.2006.05.024. Cancer Cell. 2006. PMID: 16843264 Free PMC article.
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, Takigawa N, Kiura K, Shimizu K, Date H, Minna JD, Varella-Garcia M, Lam WL, Gazdar AF, Toyooka S. Kubo T, et al. Among authors: peyton m. Int J Cancer. 2009 Apr 15;124(8):1778-84. doi: 10.1002/ijc.24150. Int J Cancer. 2009. PMID: 19117057 Free PMC article.
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF. Gandhi J, et al. Among authors: peyton m. PLoS One. 2009;4(2):e4576. doi: 10.1371/journal.pone.0004576. Epub 2009 Feb 24. PLoS One. 2009. PMID: 19238210 Free PMC article.
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK. Sos ML, et al. Among authors: peyton m. Cancer Res. 2009 Apr 15;69(8):3256-61. doi: 10.1158/0008-5472.CAN-08-4055. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351834 Free PMC article.
154 results